Vaginal bleeding after an IVF transfer is every patient’s worst fear — and remarkably common, affecting an estimated 25-40% of IVF pregnancies in the first trimester, often from a subchorionic hematoma (SCH). The reassuring core numbers: 70-85% of SCHs resolve by 16-18 weeks, and 60-75% of SCH pregnancies end in a live birth.
What Is a Subchorionic Hematoma?
A subchorionic hematoma is blood pooling between the chorion (outer fetal membrane) and the uterine wall. Where the chorion separates from the decidua (transformed uterine lining), blood from decidual vessels collects in the gap.
SCH is classified by position relative to the gestational sac:
- Retrochorial: behind the chorion and sac — most common, resolves alone
- Subchorionic (lateral): between chorion and uterine wall — slightly higher risk
- Marginal (supracervical): near the internal cervical os — often heavier bleeding
On ultrasound it is a crescent or oval anechoic (black) area between sac and wall; aging shifts it to hypoechoic, then echogenic, which means clot organization, not worsening.
How SCH Size Is Graded
Risk tracks size: the standard system grades hematomas by the percentage of sac circumference involved.
| Grade | Circumference Covered | Typical Appearance | Clinical Significance |
|---|---|---|---|
| Mild (Grade 1) | <20% | Small, localized | Minimal risk; most resolve spontaneously |
| Moderate (Grade 2) | 20-50% | Medium | Moderate risk; monitoring required |
| Severe (Grade 3) | >50% | Large, may distort sac | Highest risk; close surveillance |
A second system grades absolute volume: small <10 mL (low risk), medium 10-30 mL (moderate), large 30-60 mL (high), massive >60 mL (very high). Read both — 60% of circumference at 5 mm thickness can carry less risk than 30% at 20 mm.
How Common Is SCH in IVF vs Natural Conception?
Prevalence ranges widely, but data consistently show more SCH in IVF pregnancies than in spontaneous conceptions.
| Population | SCH Prevalence Range | Notes |
|---|---|---|
| Natural conception | 4-22% | Low end unselected, high end symptomatic |
| IVF — fresh transfer | 8-42% | Range reflects timing and criteria |
| IVF — frozen embryo transfer | 6-34% | Possibly lower than fresh |
| IVF — HRT-prepared cycles | 12-35% | Hormonal prep may raise decidual fragility |
| IVF — PGT cycles | 10-30% | No clear increase over standard IVF |
Compiled from retrospective cohorts and systematic reviews published 2010-2026.
Why Might IVF Pregnancies Have Higher SCH Rates?
Five mechanisms are proposed; none proven. Supraphysiologic estrogen — estradiol runs 10-20 times natural-cycle values after stimulation, raising endometrial vascular permeability.
Progesterone-induced decidual changes — the decidualized lining every IVF patient receives is more vascular and possibly more prone to separation. The other three: mechanical disturbance during embryo transfer; aspirin and anticoagulants, which do not cause SCH but enlarge one once formed; and multiple gestation, common in IVF, with a larger placental surface.
Does SCH Affect IVF Pregnancy Outcomes?
Yes — mainly through hematoma size and location, bleeding symptoms, and maternal age and obstetric history. Small hematomas barely move the odds; large and massive ones matter.
Impact on Miscarriage Rates
| Hematoma Characteristic | Miscarriage Rate (Approx.) | vs No SCH |
|---|---|---|
| No SCH (control) | 8-15% | — |
| Small SCH, no bleeding | 10-18% | No significant increase |
| Small SCH, with bleeding | 14-22% | Mild increase |
| Moderate SCH | 18-30% | Moderate increase (1.5-2x) |
| Large SCH (>30 mL or >50% circumference) | 30-50% | Significant increase (2-3x) |
| Massive SCH (>60 mL) | 40-65% | Marked increase (3-4x) |
| SCH with bridging vessels | 35-55% | High-risk subset |
These figures synthesize a meta-analysis of 12 studies covering 4,287 SCH pregnancies (Tuuli et al., 2011, Obstetrics & Gynecology), which reported an overall miscarriage odds ratio of 2.18 (95% CI 1.44-3.29), updated with cohort studies through 2025.
Impact on Live Birth Rates
Live-birth data are more encouraging than miscarriage data.
| Hematoma Characteristic | Live Birth Rate | Preterm Birth Rate |
|---|---|---|
| No SCH | 85-92% | 8-12% |
| Small SCH | 78-88% | 10-15% |
| Moderate SCH | 65-78% | 14-20% |
| Large/massive SCH | 45-65% | 20-35% |
Other Obstetric Outcomes
Beyond miscarriage and live birth, SCH is linked to several complications on less consistent evidence:
- Placental abruption: OR 1.5-2.0
- Preterm premature rupture of membranes (PPROM): OR 1.4-2.2
- Preterm birth: OR 1.3-1.8
- Low birth weight: OR 1.3-1.7
- Fetal growth restriction (FGR): OR 1.2-1.5
The mechanism is shared: a large hematoma creates a plane of separation between chorion and decidua that extends as the pregnancy grows; for a small asymptomatic SCH it should not change management.
Factors That Do NOT Increase Risk
Four commonly feared factors show no association with worse outcomes:
- Vaginal bleeding that resolves spontaneously
- Maternal age under 35 (analyzed independently of SCH size)
- A SCH in a previous pregnancy
- Singleton versus twin gestation, once adjusted for SCH size
What Are the Symptoms and How Is SCH Diagnosed?
SCH ranges from silent to obvious bleeding — roughly 30-60% of hematomas on ultrasound are incidental findings without symptoms.
Presentations:
- Painless bleeding, bright red to dark brown
- Mild cramping, pelvic pressure or passing clots
- Intermittent brown discharge over days to weeks, or no symptoms at all
The key distinction: the bleeding comes from the hematoma, not the sac or placenta — the embryo stays intact unless the hematoma spans more than 50-60% of the chorionic surface, so bleeding heaviness correlates poorly with outcome.
Transvaginal ultrasound between 6 and 12 weeks makes the diagnosis on four criteria:
- An anechoic (dark) crescent or oval between chorion and myometrium
- An intact sac with yolk sac and fetal pole
- Cardiac activity (visible from about 6-6.5 weeks)
- A closed internal os, excluding insufficiency or miscarriage in progress
Early on an SCH can mimic a second sac or physiologic fluid, so a repeat scan in 7-14 days settles it.
What Raises SCH Risk in IVF Patients?
| Risk Factor | Strength | Mechanism |
|---|---|---|
| Advanced maternal age, 38+ | Moderate | Greater decidual vascular fragility |
| Fresh embryo transfer | Low-moderate | Supraphysiologic estrogen → endometrial vascularity |
| High estradiol at trigger | Moderate | Elevated peak E2 linked to bleeding |
| Low-dose aspirin or heparin/LMWH | Low (worsens existing SCH) | Does not cause SCH but enlarges it |
| Submucosal fibroids | Moderate | Focal decidual thinning over fibroid |
| Prior uterine surgery (cesarean, myomectomy) | Low-moderate | Scar tissue alters decidual attachment |
| Thrombophilia (inherited or acquired) | Low | Controversial — studies conflict |
| Multiple gestation | Moderate | Larger placental surface |
| Smoking | Moderate | Impaired decidual vascular integrity |
| Autoimmune disease (SLE, APS) | Low-moderate | Via thrombophilia or anticoagulant use |
Patients stacking several factors should plan monitoring with their fertility team — a baseline ultrasound at 6-7 weeks is often reasonable.
How Is SCH Managed in an IVF Pregnancy?
Most management is supportive: 70-85% of hematomas resolve spontaneously by 16-18 weeks.
Active Monitoring
For small-to-moderate asymptomatic SCH:
- Ultrasound: repeat scan in 7-14 days to reassess size, location and development
- Activity: no restriction has evidence support — advice against heavy lifting rests on judgment
- Pelvic rest: no intercourse, orgasm or instrumentation until resolution; no direct evidence sex worsens SCH, but contractions could extend separation
- Flying: unstudied for SCH; general obstetrics allows flying to 36 weeks, most clinicians accept flights under 3 hours for asymptomatic SCH and avoid long-haul travel until resolution (typically 14-18 weeks)
- Anxiety: measurements fluctuate normally, so avoid weekly “just checking” scans; 70-85% of SCHs resolve untouched
Medication Adjustments for IVF Patients
Never change a prescribed medication on your own.
Progesterone support: continue every product exactly as prescribed; no evidence shows progesterone causes or worsens SCH.
Low-dose aspirin depends entirely on the indication:
- Empirical use, no defined reason: most pause it until resolution; the prescriber decides.
- Documented indication (antiphospholipid syndrome, thrombophilia, prior preeclampsia): thrombotic risk of stopping usually outweighs hematoma risk, so aspirin continues, sometimes reduced from 100 mg to 75 mg.
- Never stop aspirin prescribed for cardiac or thrombotic disease without consulting the prescriber.
Low-molecular-weight heparin (LMWH): same logic but higher stakes — documented thrombophilia or APS means it continues, since thrombotic loss exceeds hematoma-extension risk. Dose changes need hematology input and scans move to every 2 weeks; tranexamic acid appears in severe cases without standard backing.
Vaginal estrogen in an HRT frozen-transfer cycle: continue as directed — early pregnancy estrogen does not raise SCH risk.
Intervention in Severe Cases
For massive or symptomatic hematomas with heavy bleeding or pain:
- Hospital observation for IV fluids and serial hemoglobin
- Transfusion rarely needed — considered below 8 g/dL or with symptomatic anemia
- Tranexamic acid appears in case series, but no RCT supports routine use
- Higher progesterone (e.g. 400 mg to 600 mg daily vaginal) in some protocols, on case-series evidence
- Surgical evacuation contraindicated unless a miscarriage coincides
Does SCH Require Bed Rest?
Bed rest is entrenched in reproductive medicine and poorly evidenced: a 2020 systematic review in the Journal of Maternal-Fetal and Neonatal Medicine of 8 studies on activity restriction in first-trimester bleeding found no benefit for miscarriage risk, gestational age or neonatal outcomes.
The 2021 Cochrane update on threatened miscarriage concluded:
“There is insufficient evidence to support routine bed rest for women with threatened miscarriage to prevent pregnancy loss.” — Cochrane systematic review, bed rest for threatened miscarriage, 2021
Even so, surveys show 65-80% of clinicians still recommend some activity restriction — caution in an evidence gap.
What to Do Instead
Evidence does not support strict bed rest, but moderate limits have never been shown to harm either.
- Small SCH, no bleeding → no restrictions
- Small SCH, light bleeding → 2-3 quiet days, then normal activity
- Moderate SCH with bleeding → pelvic rest, no heavy lifting or high-impact exercise
- Large SCH with heavy bleeding → individualized advice, given the risk profile
Strict bed rest has real costs — venous thromboembolism, muscle atrophy, bone loss, psychological distress — so most specialists recommend modified activity.
When Does SCH Resolve?
Most hematomas follow a predictable timeline: 70-85% are gone on ultrasound by 14-18 weeks, and more than 90% by 18-20 weeks.
| Stage | Typical Course |
|---|---|
| Diagnosis (6-10 weeks) | Found at the early scan |
| 7-14 days after diagnosis | Follow-up scan: 40-50% of small SCHs already shrink |
| 10-14 weeks | Bleeding peak — may expand as chorion frondosum becomes the definitive placenta |
| 14-18 weeks | 70-85% resolved; bleeding usually stops |
| 18-20 weeks | >90% resolved; persistence beyond 20 weeks warrants specialist review |
Bleeding follows three patterns, all compatible with a good outcome while the hematoma is not expanding:
- Acute: one episode settling within 3-7 days as the hematoma drains
- Intermittent: spotting over 2-6 weeks as pressure releases
- Chronic: low-grade spotting until resolution
See the step-by-step IVF process guide.
What Do Real SCH Cases Look Like?
Four anonymized cases — adapted from real patients with pseudonyms — span resolution to loss.
Case 1: Sarah — a Small SCH That Vanished
Sarah, 34, conceived in a fresh IVF cycle in Barcelona for unexplained infertility; her 7-week scan showed a live single pregnancy plus a 12 x 6 x 8 mm SCH — about 5% of sac circumference, roughly 3 mL — with no bleeding.
“I was terrified. After everything we went through to get pregnant, the last thing I wanted was a ‘complication’ label,” Sarah says. Management was nothing: no restrictions, no medication changes, one repeat scan in 14 days.
The 9-week scan showed complete resolution — “The ultrasound technician actually had trouble finding it” — and she delivered a healthy boy at 39 weeks.
Lesson: a small asymptomatic SCH in a low-risk patient is clinically minor; the main intervention is reassurance.
Case 2: Emma — Moderate SCH While on Aspirin for APS
Emma, 39, conceived by frozen embryo transfer in London on 100 mg aspirin daily for antiphospholipid syndrome (APS) found after two earlier losses; her 7-week scan showed a 28 x 15 x 12 mm SCH covering about 35% of the sac, after three days of brown spotting.
“The spotting started on a Saturday. By Monday I had convinced myself the pregnancy was over,” Emma recalls. Her rheumatologist and fertility specialist kept aspirin going at 75 mg, with scans every 2 weeks.
It shrank over 8 weeks and resolved by 16 weeks; aspirin returned to 100 mg at 12 weeks, and Emma delivered a healthy girl at 38 weeks by planned cesarean for breech. “Knowing that stopping aspirin could cause a loss I couldn’t even see on a scan helped me accept the bleeding.” Lesson: when anticoagulation is indicated, stopping it is usually the bigger risk.
Case 3: Maya — Heavy Bleeding from a Large SCH
Maya, 41, conceived in her second IVF cycle with PGT-A in New York — AMH 0.8 ng/mL, one euploid embryo from two retrievals. At 8 weeks she soaked through her clothing with bright red blood in 30 minutes and went to the emergency room.
“I was in a meeting. I stood up and felt blood running down my legs. I thought I was miscarrying right there,” Maya says. The scan showed a heartbeat — and a 50 x 30 x 25 mm SCH covering more than 60% of the sac (about 55 mL), cervix closed.
She was observed 48 hours as hemoglobin fell from 12.8 to 10.9 g/dL, no transfusion, then rested a week with lifting and intercourse restricted. The hematoma measured about 25 mL at 10 weeks and 20 x 12 x 8 mm at 12 weeks, gone by 16 weeks; she delivered a 3.2 kg boy at 39 weeks.
“That embryo survived a hematoma, two retrievals, a biopsy and a frozen transfer.” Lesson: heavy bleeding need not end a pregnancy when a heartbeat is present at diagnosis.
Case 4: Nicole — Loss from an Expanding SCH
Nicole, 37, conceived in her first IVF cycle in Bangkok; the 7-week scan showed yolk sac, a heartbeat and a small 15 x 8 x 6 mm SCH, and two days of mild spotting at 8 weeks resolved alone.
At the 9-week scan there was no cardiac activity — development had stopped at about 8 weeks 3 days and the SCH had grown to 35 x 20 x 15 mm, covering roughly 45% of the sac. “The technician went quiet. I knew before she said anything,” Nicole recalls.
Tissue testing after evacuation showed trisomy 16, a random error unrelated to age: the SCH was a consequence of the failing pregnancy, not its cause. “If I had not had the POC testing, I would have blamed the hematoma forever.”
Nicole is now 28 weeks pregnant after a frozen transfer of a euploid embryo from that first retrieval, with no recurrence. Lesson: POC testing after a loss separates causation from correlation.
When Should You Seek Emergency Care?
None of these signs predicts an outcome on its own, but all need evaluation.
Emergency department immediately:
- Bleeding soaking a pad within 1 hour or faster
- Clots larger than a lemon
- Severe pain unrelieved by rest
- Dizziness or fainting on standing
- Fever above 38.0°C (100.4°F)
- Heavy bleeding with disappearing pregnancy symptoms
Call your clinic within 24 hours:
- New spotting or light bleeding, even painless
- Brown discharge turning bright red
- Mild cramping that comes and goes
- A sudden drop in pregnancy symptoms
If unsure, get checked: one quick ultrasound buys reassurance or timely intervention.
FAQ
Q: Does SCH mean I will miscarry?
No — 60-75% of SCH pregnancies end in a live birth; risk turns on size, location and maternal age, and with a heartbeat at diagnosis even large SCHs carry a 45-65% live-birth rate.
Q: Can SCH be prevented in future IVF cycles?
No strategy is proven; some clinicians switch large or recurrent SCH cases to frozen transfers, or lower the gonadotropin dose to limit estradiol, on small retrospective evidence only; 70-85% resolve without intervention.
Q: Should I stop aspirin if I have SCH?
Never decide alone: with a documented indication (cardiac disease, thrombophilia, APS) continuing is usually safer than stopping; empirical users may pause until resolution, at 75 mg rather than 100 mg.
Q: Does SCH affect the baby’s development?
Not directly: a very large hematoma can compromise nutrient and oxygen exchange across part of the placenta, so large or persistent SCHs get growth scans at 28-32 weeks; most babies arrive at normal birth weight.
Q: Is bed rest recommended for SCH?
No — the 2021 Cochrane review found no benefit from activity restriction for threatened miscarriage, and strict bed rest carries clot and muscle-loss risks; 70-85% of SCHs resolve by 16-18 weeks regardless.
Q: Will SCH show up again in my next pregnancy?
Usually not: recurrence is estimated at 5-15%, and a large retrospective study found no increase in later spontaneous pregnancies. Risk rises with antiphospholipid syndrome, chronic hypertension or thrombophilia.
Q: Does SCH mean I need a cesarean?
No — SCH alone is not a cesarean indication: once resolved, typically by weeks 14-18, vaginal delivery is appropriate unless another obstetric factor applies; persistence to term is rare.
Q: Does progesterone cause or worsen SCH?
No — no evidence progesterone causes SCH, which appears in 8-42% of IVF pregnancies regardless of protocol. Keep taking it as prescribed: abrupt withdrawal can remove the luteal support maintaining an IVF conception.
Your SCH Monitoring Checklist
A structured plan turns the diagnosis from panic into process: grade size by circumference and volume with a medication list at diagnosis, re-measure at 7-14 days, confirm resolution by 14-18 weeks, and request POC genetic testing after an unfavorable outcome
Find clinics with transparent monitoring protocols in our directory, or contact the ProIVF team to prepare questions.
About this article: Written by the ProIVF Medical Editorial Team from peer-reviewed studies indexed in PubMed and Cochrane — the Tuuli et al. (2011, Obstetrics & Gynecology) meta-analysis of 12 SCH studies, the 2021 Cochrane review of bed rest for threatened miscarriage, IVF cohort studies of SCH outcomes and ASRM guidance on first-trimester bleeding — with AI-assisted tools used only for literature organization and initial drafting, and review by the ProIVF Medical Advisory Board.
Last updated: July 20, 2026. Informational only, not medical advice. SCH management must be individualized — consult your fertility specialist, obstetrician and, where relevant, hematology or maternal-fetal medicine specialists. Background: CDC ART success-rate data, ASRM, ESHRE.
